Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2681

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2681
---
 general market or economic conditions. Furthermore,
an active trading market for our securities may never develop or, if developed, it may not be sustained. Holders of our securities may
be unable to sell their securities unless a market can be established and sustained.

The
market price of our securities may decline as a result market factors.

Fluctuations
in the price of our securities could contribute to the loss of all or part of your investment. If an active market for our securities
develops and continues, the trading price of our securities could be volatile and subject to wide fluctuations in response to various
factors, some of which are beyond our control. Any of the factors listed below could have a material adverse effect on your investment
in our securities and our securities may trade at prices significantly below the price you paid for our securities. In such circumstances,
the trading price of our securities may not recover and may experience a further decline.

The
market price of our securities may decline as a result for a number of other reasons including:

    ●
    if
    the effect of the Business Combination on our business and prospects is not consistent with the expectations of securities or industry
    analysts;

    ●
    if
    we do not achieve the perceived benefits of the Business Combination as rapidly or to the extent anticipated by securities or industry
    analysts;

    ●
    actual
    or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar
    to us;

    ●
    changes
    in the market’s expectations about our results of operations;

    ●
    success
    of competitors;

    ●
    changes
    in financial estimates and recommendations by securities analysts concerning us or the biopharmaceutical industry in general;

    ●
    operating
    and share price performance of other companies that investors deem comparable to us;

    ●
    our
    ability to market new and enhanced products and technologies on a timely basis;

129

    ●
    changes
    in laws and regulations affecting our business;

    ●
    our
    ability to meet compliance requirements;

    ●
    commencement
    of, or involvement in, litigation involving us;

    ●
    changes
    in our capital structure, such as future issuances of securities or the incurrence of additional debt;

    ●
    the
    volume of our securities available for public sale; or

    ●
    any
    major change in our board of directors or management.

Certain